Harmony Biosciences Holdings, Inc. (HRMY) › Cost of RevenueHarmony Biosciences Holdings, Inc. (HRMY) — Cost of RevenueAnnual figures by fiscal year, from SEC filings.2019: $1.58M2020: $27.74M2021: $55.52M2022: $83.48M2023: $121.24M2024: $156.81M2025: $198.34M$198.34M2019Cost of Revenue (USD)2025Fiscal YearCost of RevenueChange YoY2025$198.34M+26.5%2024$156.81M+29.3%2023$121.24M+45.2%2022$83.48M+50.4%2021$55.52M+100.2%2020$27.74M+1658.9%2019$1.58M—Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share